Print ISSN:-2395-1354
Online ISSN:-2395-1362
CODEN : IJOSHC
Original Article
Author Details :
Volume : 10, Issue : 1, Year : 2024
Article Page : 23-28
https://doi.org/10.18231/j.ijos.2024.004
Abstract
Background: Plantar Fasciitis (PF) is a prevalent musculoskeletal condition causing heel pain, with approximately 1 million annual U.S. physician visits. It is more common in women, aged 45-64, and obese individuals. Diagnosis relies on clinical history and examination, and various treatments target pain relief, though consensus on the most effective modality is lacking. Corticosteroid injections are commonly used but pose risks.
Materials and Methods: This six-month prospective randomized controlled trial with 50 individuals assessed the efficacy of corticosteroid versus placebo injections for resistant PF. Ultrasound-guided injections were administered, and outcomes were measured at 3 weeks and 3 months.
Results: Results indicated significant improvement in pain scores, Ankle and Hindfoot scores, and plantar fascia thickness with corticosteroid injections compared to placebo. No serious adverse events were observed.
Conclusion: Corticosteroids aim to reduce inflammation, and studies link decreased plantar fascia thickness to pain relief. Ultrasound guidance enhances precision in delivery. While some protocol limitations exist, this trial contributes valuable insights into the pharmacological effects of corticosteroids in PF treatment, aiding in evidence-based recommendations.
Keywords: Corticosteroid injection, Heel pain, Plantar fasciitis, Platelet rich plasma, Plantar fascia thickness, Ultrasound guidance, Visual analog scale.
How to cite : Vatsa G, Suman S, Anshuman K, Ultrasound-guided injection of corticosteroid versus placebo in management of plantar fasciitis. Indian J Orthop Surg 2024;10(1):23-28
This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.